The Northwest Community Oncology Program (NWCCOP) has been in operation since 1983. It consists of 35 participating Medical and Radiation Oncologists located in Southwest Washington, Portland, OR, and Boise, ID. It utilizes five research bases including the Southwest Oncology Group, National Surgical Adjuvant Breast and Bowel Project, University of Rochester Cancer Center, M.D. Anderson Cancer Center, and the H. Lee Moffitt Cancer Center. The objective of the NWCCOP is to provide community oncologists with the opportunity to participate in a variety of treatment and cancer prevention and control research trials provided by these research bases. Such trials are reviewed for applicability to the local community, and prior to activation, they must meet successful Investigational Review Board approval. It is then through this mechanism that the latest and up to-date treatment programs are made available to community patients. It remains successful in its accrual to these studies. The NWCCOP has also participated in the latest prevention trials for breast and prostate cancer, to include the STAR and SELECT trials, respectively. In addition, the NWCCOP participates in a variety of trials concerning symptom management in various cancers. The funds obtained through a successful application will be used to support the administration of these activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035281-28
Application #
8143551
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Program Officer
Kelaghan, Joseph
Project Start
1983-09-15
Project End
2012-05-31
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
28
Fiscal Year
2011
Total Cost
$748,188
Indirect Cost
Name
Tacoma General Hospital
Department
Type
DUNS #
151474301
City
Tacoma
State
WA
Country
United States
Zip Code
98405
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9

Showing the most recent 10 out of 108 publications